COVID Data Link Severe Infections to Cancer Recurrence, Especially Within 1 Year
Updated
Updated · Los Angeles Times · Jun 15
COVID Data Link Severe Infections to Cancer Recurrence, Especially Within 1 Year
1 articles · Updated · Los Angeles Times · Jun 15
Summary
U.K. Biobank records from 2020 showed cancer survivors who caught COVID were significantly more likely to die from recurrent cancer, especially in the year after infection; a U.S. breast cancer database found more metastatic lung tumors after remission.
University of Colorado researchers first saw the pattern in early 2022, when mice with dormant breast cancer cells infected with influenza or SARS-CoV-2 were far more likely to develop aggressive lung tumors; the findings were published last year in Nature.
IL-6, a cytokine elevated in severe COVID, emerged as one possible mechanism because chronically high levels are already linked to recurrence and metastasis, though some co-authors argue mitochondrial dysfunction may be the key driver instead.
Researchers stressed the evidence is still preliminary and does not show COVID causes cancer; the concern is that severe viral inflammation may reactivate dormant cancer cells, making vaccination and other precautions advisable for vulnerable patients.
Is your immune system's fight against viruses accidentally waking up dormant cancer?
Should cancer screenings become routine after recovering from severe viral infections?
Cancer Survivors at Risk: COVID-19 Variants, Treatment Disruptions, and the Awakening of Dormant Tumor Cells
Overview
As of mid-2026, the ongoing evolution of COVID-19 and its variants continues to create complex challenges for cancer survivors. The scientific community is actively investigating how COVID-19 infections disrupt cancer treatment, with over half of reported treatment delays directly linked to the virus, especially within the first month after infection. These disruptions can reduce the effectiveness of therapies and increase the risk of cancer recurrence. While much has been learned, many questions remain about the long-term impact of COVID-19 on those with a history of cancer, highlighting the need for continued research and vigilant care.